Biogen kept information on its closely watched Alzheimer's drug BAN2401 well-guarded during a Tuesday earnings call, choosing instead to focus on the durability of its multiple sclerosis portfolio and the growth of its muscular degeneration business.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,